Indivior Pharmaceuticals, Inc. (INDV)

NASDAQ · Manufacturing · Pharmaceutical preparations

$35.69−$0.1300 (−0.36%)As of the Sep 28, 2026 close; data may be delayed.

INDV price, last 12 months

Sep 16, 2025Sep 28, 2026

Daily closes over the last 260 trading sessions: +56.7%. Highest close $41.83 on Jun 26, 2026, lowest $22.51 on Sep 19, 2025. Market data may be delayed.

Key stats

Previous close: $35.82
Open: $35.90
Day range: $35.43 – $35.91
52-week range: $22.56 – $42.81
Volume: 34.1K
Avg volume (20 days): 1.9M
Market cap: $4.2B

Performance

1W+0.5%

1M+1.1%

3M−13.5%

6M+23.2%

YTD−0.5%

1Y+56.5%

vs S&P 500, 1Y+39.8 pts

Technicals and fundamentals

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Sector: Manufacturing
Industry: Pharmaceutical preparations
Listed on: NASDAQ
Market cap: $4.2B

indivior.com

Technicals and fundamentals

Technicals

RSI (14)48.5mid-range

vs 50-day average−3.9%

vs 200-day average−0.1%price below both averages

MACDAbove signal

Daily range (ATR)2.7%average true range, % of price

52w low $22.5652w high $42.81

Where price sits today against its own history. A description, not a forecast.

Valuation

P/E (trailing)12.00.49x Manufacturing median (24.4)

P/E (forward)7.3

PEG—

Price / sales3.20

Price / book−20.32

EV / EBITDA10.1

P/E since Jun 111.2 – 13.9

Company figures as of Sep 25, 2026.

Analysts

Consensus—— on 1 (strong buy) to 5 (strong sell)

Analysts4

Average target$49.00+37.3% from today

Price targets are opinions and tend to lean optimistic. Only 4 analysts cover it, so one view moves the average.

Earnings

Quarter ended	EPS	YoY	Revenue	YoY
Jun '26	0.98	+600%	$343M	+14%
Mar '26	0.69	+82%	$317M	+19%
Dec '25	0.79	—	$358M	—
Sep '25	0.33	—	$314M	—
Jun '25	0.14	—	$302M	—
Mar '25	0.38	—	$266M	—

By the quarter each report covers, against the same quarter a year earlier. Growth from a loss is left blank: a percentage there reads backwards.

Dividends & splits

Paid, last 12 months—

Yield at today's price—

Next dividend$8.13ex-dividend Oct 30, 2026; declared, not yet paid

Change vs the year before—

Payout ratio270%share of earnings paid out

Seasonality

+3.3

-2.8

-1.3

+7.8

+4.7

+5.5

+3.3

-0.4

-6.3

-2.0

+10.3

+2.6

Average return in each calendar month, Jul 31, 2023 to Aug 31, 2026. 4 years is 4 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.

	Q1 FY2025Sep 30, 2024	Q4 FY2024Dec 31, 2024	Q1 FY2025Mar 31, 2025	Q2 FY2025Jun 30, 2025	Q3 FY2025Sep 30, 2025	Q4 FY2025Dec 31, 2025	Q1 FY2026Mar 31, 2026	Q2 FY2026Jun 30, 2026
Income
Revenue	$307.0M	$299.0M	$266.0M	$302.0M	$314.0M	$358.0M	$317.0M	$343.0M
vs a year before	—	—	−6%	+1%	+2%	+20%	+19%	+14%
Gross margin	78.5%	83.6%	83.1%	82.8%	73.3%	81.6%	87.4%	85.7%
Operating income	$35.0M	$46.0M	$66.0M	$72.0M	$43.0M	$81.0M	$137.0M	$160.0M
Operating margin	11.4%	15.4%	24.8%	23.8%	13.7%	22.6%	43.2%	46.7%
Net income	$22.0M	$21.0M	$47.0M	$18.0M	$42.0M	$102.0M	$89.0M	$122.0M
Net margin	7.2%	7.0%	17.7%	6.0%	13.4%	28.5%	28.1%	35.6%
EPS, diluted	0.16	0.16	0.38	0.14	0.33	0.79	0.69	0.98
vs a year before	—	—	−16%	—	+106%	+394%	+82%	+600%
Cash flow
From operations	$2.0M	−$17.0M	$75.0M	$158.0M	−$39.0M	−$221.0M	−$9.0M	$229.0M
Capital spending	$7.0M	$16.0M	$5.0M	$17.0M	$20.0M	$24.0M	$20.0M	$7.0M
Free cash flow	−$5.0M	−$33.0M	$70.0M	$141.0M	−$59.0M	−$245.0M	−$29.0M	$222.0M
At period end
Cash	—	$319.0M	$372.0M	$510.0M	$445.0M	$195.0M	$175.0M	$222.0M
Debt	—	$315.0M	$311.0M	$308.0M	$304.0M	$290.0M	$486.0M	$487.0M
Shareholders' equity	−$310.0M	−$337.0M	−$285.0M	−$257.0M	−$207.0M	−$98.0M	−$144.0M	−$208.0M

Q1 FY2025Sep 30, 2024

Q4 FY2024Dec 31, 2024

Q1 FY2025Mar 31, 2025

Q2 FY2025Jun 30, 2025

Q3 FY2025Sep 30, 2025

Q4 FY2025Dec 31, 2025

Q1 FY2026Mar 31, 2026

Q2 FY2026Jun 30, 2026

Income

Revenue

$307.0M

$299.0M

$266.0M

$302.0M

$314.0M

$358.0M

$317.0M

$343.0M

vs a year before

—

−6%

+1%

+2%

+20%

+19%

+14%

Gross margin

78.5%

83.6%

83.1%

82.8%

73.3%

81.6%

87.4%

85.7%

Operating income

$35.0M

$46.0M

$66.0M

$72.0M

$43.0M

$81.0M

$137.0M

$160.0M

Operating margin

11.4%

15.4%

24.8%

23.8%

13.7%

22.6%

43.2%

46.7%

Net income

$22.0M

$21.0M

$47.0M

$18.0M

$42.0M

$102.0M

$89.0M

$122.0M

Net margin

7.2%

7.0%

17.7%

6.0%

13.4%

28.5%

28.1%

35.6%

EPS, diluted

0.16

0.38

0.14

0.33

0.79

0.69

0.98

vs a year before

—

−16%

—

+106%

+394%

+82%

+600%

Cash flow

From operations

$2.0M

−$17.0M

$75.0M

$158.0M

−$39.0M

−$221.0M

−$9.0M

$229.0M

Capital spending

$7.0M

$16.0M

$5.0M

$17.0M

$20.0M

$24.0M

$20.0M

$7.0M

Free cash flow

−$5.0M

−$33.0M

$70.0M

$141.0M

−$59.0M

−$245.0M

−$29.0M

$222.0M

At period end

Cash

—

$319.0M

$372.0M

$510.0M

$445.0M

$195.0M

$175.0M

$222.0M

Debt

—

$315.0M

$311.0M

$308.0M

$304.0M

$290.0M

$486.0M

$487.0M

Shareholders' equity

−$310.0M

−$337.0M

−$285.0M

−$257.0M

−$207.0M

−$98.0M

−$144.0M

−$208.0M

Indivior Pharmaceuticals, Inc. (INDV)

INDV price, last 12 months

Key stats

Performance

Technicals and fundamentals

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. (INDV)

INDV price, last 12 months

Key stats

Performance

Technicals and fundamentals

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

About Indivior Pharmaceuticals, Inc.

News

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

News

INDV price, last 12 months

Key stats

Performance

Technicals and fundamentals

About Indivior Pharmaceuticals, Inc.

Recent news about INDV

Chart INDV with indicators, scan for setups and get alerts

INDV price, last 12 months

Key stats

Performance

Technicals and fundamentals

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

About Indivior Pharmaceuticals, Inc.

Recent news about INDV

News

Chart INDV with indicators, scan for setups and get alerts

Technicals

Valuation

Analysts

Earnings

Dividends & splits

Seasonality

Financials

News